Johanna Stachelscheid,Qu Jiang,Christoph Aszyk,Kathrin Warner,Nadine Bley,Tony Müller,Olga Vydzhak,Konstantinos Symeonidis,Giuliano Crispatzu,Petra Mayer,Stuart James Blakemore,Gudrun Goehring,Sebastian Newrzela,Stephanie Hippler,Sandra Robrecht,Karl-Anton Kreuzer,Christian Pallasch,Marcus Krüger,Axel Lechner,Kirsten Fischer,Stephan Stilgenbauer,Dirk Beutner,Michael Hallek,Daniel Auguin,Stefan Hüttelmaier,Johannes Bloehdorn,Elena Vasyutina,Marco Herling

Abstract:Upregulation of the proto-oncogene T-cell leukemia/lymphoma 1A (TCL1A) is causally implicated in various B-cell and T-cell malignancies. High-level TCL1A correlates with aggressive disease features and inferior clinical outcomes. However, the molecular and cell biological consequences of, particularly nuclear, TCL1A are not fully elucidated. We observed here in mouse models of subcellular site-specific TCL1A-induced lymphomagenesis that TCL1A exerts a strong transforming impact via nuclear topography. In proteomic screens of TCL1A-bound molecules in chronic lymphocytic leukemia (CLL) cells and B-cell lymphoma lines, we identified regulators of cell cycle and DNA repair pathways as novel TCL1A interactors, particularly enriched under induced DNA damage and mitosis. By functional mapping and in silico modeling, we specifically identified the mitotic checkpoint protein, cell division cycle 20 (CDC20), as a direct TCL1A interactor. According to the regulatory impact of TCL1A on the activity of the CDC20-containing mitotic checkpoint and anaphase-promoting complexes during mitotic progression, TCL1A overexpression accelerated cell cycle transition in B-cell lymphoma lines, impaired apoptotic damage responses in association with pronounced chromosome missegregation, and caused cellular aneuploidy in Eμ-TCL1A mice. Among hematopoietic cancers, CDC20 levels seem particularly low in CLL. CDC20 expression negatively correlated with TCL1A and lower expression marked more aggressive and genomically instable disease and cellular phenotypes. Knockdown of Cdc20 in TCL1A-initiated murine CLL promoted aneuploidy and leukemic acceleration. Taken together, we discovered a novel cell cycle-associated effect of TCL1A abrogating controlled cell cycle transition. This adds to our concept of oncogenic TCL1A by targeting genome stability. Overall, we propose that TCL1A acts as a pleiotropic adapter molecule with a synergistic net effect of multiple hijacked pathways.

Proto-oncogene TCL1: more than just a coactivator for Akt

The protooncogene TCL1 is an Akt kinase coactivator

The TCL1A oncoprotein interacts directly with the NF-kappaB inhibitor IkappaB

Identification of nerve growth factor-responsive element of the TCL1 promoter as a novel negative regulatory element

T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways

Structural basis for the co-activation of protein kinase B by T-cell leukemia-1 (TCL1) family proto-oncoproteins

The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways

TCL1: a new drug target in lymphoid and germ-cell malignancies?

Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1

Crystal structures of Tcl1 family oncoproteins and their conserved surface features

The TCL1 oncoprotein binds the RNase PH domains of the PNPase exoribonuclease without affecting its RNA degrading activity

The TCL1 family of oncoproteins: co-activators of transformation

T cell leukemia-1 modulates TCR signal strength and IFN-gamma levels through phosphatidylinositol 3-kinase and protein kinase C pathway activation

High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia

High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia

TCL1 as a hub protein associated with the PI3K/AKT signaling pathway in diffuse large B-cell lymphoma based on proteomics methods

I Kappa B Kinase Epsilon And Tank-Binding Kinase 1 Activate Akt By Direct Phosphorylation

The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL

Disruption Of Ph-Kinase Domain Interactions Leads To Oncogenic Activation Of Akt In Human Cancers

Modifying akt signaling in B-cell chronic lymphocytic leukemia cells

AKT-pathway inhibition in chronic lymphocytic leukemia reveals response relationships defined by TCL1